title: Increased rejection after liver transplantation in FK 506-treated patients is associated with viral hepatitis C disease.
authors.affiliation: Department of Surgery, University Clinic Rudolf Virchow, Free University of Berlin, Germany.
authors.forename: A R
authors.initials: AR
authors.lastname: Mueller
authors.forename: K P
authors.initials: KP
authors.lastname: Platz
authors.forename: W O
authors.initials: WO
authors.lastname: Bechstein
authors.forename: G
authors.initials: G
authors.lastname: Blumhardt
authors.forename: H
authors.initials: H
authors.lastname: Lobeck
authors.forename: U
authors.initials: U
authors.lastname: Hop
authors.forename: P
authors.initials: P
authors.lastname: Neuhaus
mesh_terms: D016572:Cyclosporine / Q000097:blood / Q000627:therapeutic use; D016903:Drug Monitoring; D006084:Graft Rejection / Q000453:epidemiology* / Q000276:immunology; D006509:Hepatitis B / Q000150:complications; D006526:Hepatitis C / Q000150:complications*; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D015994:Incidence; D008103:Liver Cirrhosis / Q000209:etiology / Q000601:surgery*; D008104:Liver Cirrhosis, Alcoholic / Q000601:surgery; D008105:Liver Cirrhosis, Biliary / Q000601:surgery; D016031:Liver Transplantation / Q000276:immunology* / Q000401:mortality; D016853:Muromonab-CD3 / Q000627:therapeutic use; D012189:Retrospective Studies; D015996:Survival Rate; D016559:Tacrolimus / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D013997:Time Factors
chemical_list: D016853:Muromonab-CD3; D016572:Cyclosporine; D016559:Tacrolimus